Jason Clay, APRN
Family · Warsaw, INNPI 1912570292
Payments from drug & device makers
Across 193 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$586
- AbbVie$541
- Lilly USA, LLC$284
- Axsome Therapeutics, Inc.$247
- AstraZeneca$161
- Inspire Medical Systems, Inc.$148
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,073100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $586 |
| AbbVie | 45 | $541 |
| Lilly USA, LLC | 17 | $284 |
| Axsome Therapeutics, Inc. | 21 | $247 |
| AstraZeneca | 10 | $161 |
| Inspire Medical Systems, Inc. | 4 | $148 |
| Vanda Pharmaceuticals Inc. | 3 | $113 |
| Lundbeck LLC | 6 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| Boehringer Ingelheim | 4 | $83 |
| Amgen | 5 | $78 |
| Exact Sciences | 4 | $67 |
| Johnson & Johnson | 3 | $56 |
| Antares Pharma, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $43 |
| Dexcom, Inc. | 2 | $41 |
| Abbott | 2 | $39 |
| Medical Device Business Services, Inc. | 1 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Pfizer | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Bayer | 2 | $27 |
| Organon | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Halozyme Inc | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Corium, LLC | 1 | $11 |
How this compares
$3,073 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 46 | $65,418 |
| EliquisApixaban | 43 | $49,569 |
| OzempicSemaglutide | 20 | $31,640 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $26,117 |
| XareltoRivaroxaban | 17 | $14,908 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,078 |
| Gabapentin | 64 | $1,834 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,815 |
| Atorvastatin Calcium | 184 | $1,606 |
| Ezetimibe | 16 | $1,325 |
| Duloxetine Hcl | 42 | $1,165 |
| Celecoxib | 29 | $1,065 |
| Omeprazole | 58 | $823 |
| Hydroxyzine Hcl | 26 | $815 |
| Pregabalin | 12 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $83 | $65,41846 claims |
| PfizerEliquis | $30 | $49,56943 claims |
| Novo NordiskOzempic | $586 | $31,64020 claims |
| Johnson & JohnsonXarelto | $56 | $14,90817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in Warsaw
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.